When Should CGT Companies Keep Manufacturing In-House?

During Cell & Gene Live, “Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?,” experts Emily Moran, Founder, 3LB Consulting, LLC and Sugu Patro, Ph.D., Senior Vice President Global Process Development at Kite, a Gilead Company shared insights into how CGT companies should think about balancing outsourced and in-house manufacturing as programs mature. They shared that critical elements tied to safety, efficacy, turnaround time, and process knowledge should remain closely controlled internally. The discussion also explored how sponsors can better manage evolving CDMO relationships over time, including protecting IP, negotiating performance-based manufacturing expectations, and maintaining leverage as programs move closer to commercialization.